{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:01:02Z","timestamp":1793779262346,"version":"4.6.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Cardiovasc. Transl. Res."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s12265-026-10839-8","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:34:17Z","timestamp":1787841257000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Emerging Myostatin and Metabolic Hormone Pathway Modulators in Cardiometabolic Disease: Mechanisms, Evidence, and Therapeutic Potential"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5767-0722","authenticated-orcid":false,"given":"Abiya","family":"Ahad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darshan","family":"Hullon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandana","family":"Akhavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Oskouyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"10839_CR1","doi-asserted-by":"publisher","first-page":"1181913","DOI":"10.3389\/fendo.2023.1181913","volume":"14","author":"M Yang","year":"2023","unstructured":"Yang M, Liu C, Jiang N, Liu Y, Luo S, Li C, et al. Myostatin: a potential therapeutic target for metabolic syndrome. Front Endocrinol (Lausanne). 2023;14:1181913. https:\/\/doi.org\/10.3389\/fendo.2023.1181913.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"10839_CR2","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.3390\/ijms22052639","volume":"22","author":"AR de Oliveira Dos Santos","year":"2021","unstructured":"de Oliveira Dos Santos AR, de Oliveira Zanuso B, Miola VFB, Barbalho SM, Santos Bueno PC, Flato UAP, et al. Adipokines, myokines, and hepatokines: crosstalk and metabolic repercussions. Int J Mol Sci. 2021;22(5):2639. https:\/\/doi.org\/10.3390\/ijms22052639.","journal-title":"Int J Mol Sci"},{"issue":"6628","key":"10839_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/387083a0","volume":"387","author":"AC McPherron","year":"1997","unstructured":"McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997;387(6628):83\u201390. https:\/\/doi.org\/10.1038\/387083a0.","journal-title":"Nature"},{"issue":"23","key":"10839_CR4","doi-asserted-by":"publisher","first-page":"12457","DOI":"10.1073\/pnas.94.23.12457","volume":"94","author":"AC McPherron","year":"1997","unstructured":"McPherron AC, Lee SJ. Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci U S A. 1997;94(23):12457\u201361. https:\/\/doi.org\/10.1073\/pnas.94.23.12457.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10839_CR5","doi-asserted-by":"publisher","first-page":"e148372","DOI":"10.1172\/JCI148372","volume":"131","author":"SJ Lee","year":"2021","unstructured":"Lee SJ. Targeting the myostatin signaling pathway to treat muscle loss and metabolic dysfunction. J Clin Invest. 2021;131(9):e148372. https:\/\/doi.org\/10.1172\/JCI148372.","journal-title":"J Clin Invest"},{"issue":"3","key":"10839_CR6","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s11010-024-05120-y","volume":"480","author":"B Wetzlich","year":"2025","unstructured":"Wetzlich B, Nyakundi BB, Yang J. Therapeutic applications and challenges in myostatin inhibition for enhanced skeletal muscle mass and functions. Mol Cell Biochem. 2025;480(3):1535\u201353. https:\/\/doi.org\/10.1007\/s11010-024-05120-y.","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"10839_CR7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.7150\/ijbs.73936","volume":"19","author":"H Tan","year":"2023","unstructured":"Tan H, Yue T, Chen Z, Wu W, Xu S, Weng J. Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine. Int J Biol Sci. 2023;19(1):66\u201388. https:\/\/doi.org\/10.7150\/ijbs.73936.","journal-title":"Int J Biol Sci"},{"key":"10839_CR8","doi-asserted-by":"publisher","first-page":"1220426","DOI":"10.3389\/fendo.2023.1220426","volume":"14","author":"M Yang","year":"2023","unstructured":"Yang M, Liu C, Jiang N, Liu Y, Luo S, Li C, et al. Fibroblast growth factor 21 in metabolic syndrome. Front Endocrinol (Lausanne). 2023;14:1220426. https:\/\/doi.org\/10.3389\/fendo.2023.1220426.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10839_CR9","doi-asserted-by":"publisher","first-page":"0832","DOI":"10.34133\/research.0832","volume":"8","author":"T Tian","year":"2025","unstructured":"Tian T, Liu M, Little PJ, Strijdom H, Weng J, Xu S. Emerging roles of GDF15 in metabolic and cardiovascular diseases. Research (Wash D C). 2025;8:0832. https:\/\/doi.org\/10.34133\/research.0832.","journal-title":"Research (Wash D C)"},{"issue":"10","key":"10839_CR10","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/nm.4393","volume":"23","author":"PJ Emmerson","year":"2017","unstructured":"Emmerson PJ, Wang F, Du Y, Liu Q, Pickard RT, Gonciarz MD, et al. The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL. Nat Med. 2017;23(10):1215\u20139. https:\/\/doi.org\/10.1038\/nm.4393.","journal-title":"Nat Med"},{"issue":"3","key":"10839_CR11","doi-asserted-by":"publisher","first-page":"loae006","DOI":"10.1093\/lifemeta\/loae006","volume":"3","author":"ZT Chen","year":"2024","unstructured":"Chen ZT, Weng ZX, Lin JD, Meng ZX. Myokines: metabolic regulation in obesity and type 2 diabetes. Life Metab. 2024;3(3):loae006. https:\/\/doi.org\/10.1093\/lifemeta\/loae006.","journal-title":"Life Metab"},{"issue":"26","key":"10839_CR12","doi-asserted-by":"publisher","first-page":"E5266","DOI":"10.1073\/pnas.1620013114","volume":"114","author":"JL Chen","year":"2017","unstructured":"Chen JL, Walton KL, Hagg A, Colgan TD, Johnson K, Qian H, et al. Specific targeting of TGF-\u03b2 family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease. Proc Natl Acad Sci U S A. 2017;114(26):E5266\u201375. https:\/\/doi.org\/10.1073\/pnas.1620013114.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10839_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/978-3-319-27511-6_5","volume":"900","author":"JL Chen","year":"2016","unstructured":"Chen JL, Colgan TD, Walton KL, Gregorevic P, Harrison CA. The TGF-\u03b2 signalling network in muscle development, adaptation and disease. Adv Exp Med Biol. 2016;900:97\u2013131. https:\/\/doi.org\/10.1007\/978-3-319-27511-6_5.","journal-title":"Adv Exp Med Biol"},{"issue":"10","key":"10839_CR14","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1161\/CIRCRESAHA.121.318241","volume":"128","author":"GD Lopaschuk","year":"2021","unstructured":"Lopaschuk GD, Karwi QG, Tian R, Wende AR, Abel ED. Cardiac energy metabolism in heart failure. Circ Res. 2021;128(10):1487\u2013513. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.318241.","journal-title":"Circ Res"},{"issue":"6","key":"10839_CR15","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1093\/cvr\/cvaa324","volume":"117","author":"NG Frangogiannis","year":"2021","unstructured":"Frangogiannis NG. Cardiac fibrosis. Cardiovasc Res. 2021;117(6):1450\u201388. https:\/\/doi.org\/10.1093\/cvr\/cvaa324.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"10839_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ageing\/afy169","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruy\u00e8re O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16\u201331. https:\/\/doi.org\/10.1093\/ageing\/afy169.","journal-title":"Age Ageing"},{"issue":"9","key":"10839_CR17","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrcardio.2014.83","volume":"11","author":"BA Borlaug","year":"2014","unstructured":"Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11(9):507\u201315. https:\/\/doi.org\/10.1038\/nrcardio.2014.83.","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"10839_CR18","doi-asserted-by":"publisher","first-page":"R99","DOI":"10.1530\/JOE-16-0021","volume":"229","author":"H Wu","year":"2016","unstructured":"Wu H, Deng X, Shi Y, Su Y, Wei J, Duan H. PGC-1\u03b1, glucose metabolism and type 2 diabetes mellitus. J Endocrinol. 2016;229(3):R99\u2013115. https:\/\/doi.org\/10.1530\/JOE-16-0021.","journal-title":"J Endocrinol"},{"issue":"12","key":"10839_CR19","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.3390\/biom13121777","volume":"13","author":"M Knapp","year":"2023","unstructured":"Knapp M, Supruniuk E, G\u00f3rski J. Myostatin and the heart. Biomolecules. 2023;13(12):1777. https:\/\/doi.org\/10.3390\/biom13121777.","journal-title":"Biomolecules"},{"issue":"3","key":"10839_CR20","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1172\/JCI60329","volume":"122","author":"PK Battiprolu","year":"2012","unstructured":"Battiprolu PK, Hojayev B, Jiang N, Wang ZV, Luo X, Iglewski M, et al. Metabolic stress-induced activation of FoxO1 triggers diabetic cardiomyopathy in mice. J Clin Invest. 2012;122(3):1109\u201318. https:\/\/doi.org\/10.1172\/JCI60329.","journal-title":"J Clin Invest"},{"issue":"7752","key":"10839_CR21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41586-019-1100-z","volume":"568","author":"GG Schiattarella","year":"2019","unstructured":"Schiattarella GG, Altamirano F, Tong D, French KM, Villalobos E, Kim SY, et al. Nitrosative stress drives heart failure with preserved ejection fraction. Nature. 2019;568(7752):351\u20136. https:\/\/doi.org\/10.1038\/s41586-019-1100-z.","journal-title":"Nature"},{"issue":"11","key":"10839_CR22","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/nm1677","volume":"13","author":"H Johnen","year":"2007","unstructured":"Johnen H, Lin S, Kuffner T, Brown DA, Tsai VW, Bauskin AR, et al. Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat Med. 2007;13(11):1333\u201340. https:\/\/doi.org\/10.1038\/nm1677.","journal-title":"Nat Med"},{"issue":"5","key":"10839_CR23","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392(5):427\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2410027.","journal-title":"N Engl J Med"},{"issue":"15","key":"10839_CR24","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024;390(15):1394\u2013407. https:\/\/doi.org\/10.1056\/NEJMoa2313917.","journal-title":"N Engl J Med"},{"issue":"3","key":"10839_CR25","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s41591-026-04204-0","volume":"32","author":"SB Heymsfield","year":"2026","unstructured":"Heymsfield SB, Aronne LJ, Montgomery P, Klickstein LB, Coleman LA, Dole K, et al. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. Nat Med. 2026;32(3):869\u201382. https:\/\/doi.org\/10.1038\/s41591-026-04204-0.","journal-title":"Nat Med"},{"issue":"24","key":"10839_CR26","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1056\/NEJMoa2409515","volume":"391","author":"JD Groarke","year":"2024","unstructured":"Groarke JD, Crawford J, Collins SM, Lubaczewski S, Roeland EJ, Naito T, et al. Ponsegromab for the treatment of cancer cachexia. N Engl J Med. 2024;391(24):2291\u2013303. https:\/\/doi.org\/10.1056\/NEJMoa2409515.","journal-title":"N Engl J Med"},{"issue":"2","key":"10839_CR27","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1007\/s11357-025-01830-3","volume":"48","author":"L Salm\u00f3n-G\u00f3mez","year":"2026","unstructured":"Salm\u00f3n-G\u00f3mez L, Catal\u00e1n V, Ram\u00edrez B, Aguas-Ayesa M, Rodr\u00edguez A, Becerril S, et al. Different association of GDF15 and FGF21 with glycemic status and aging in the context of obesity. Geroscience. 2026;48(2):2931\u201344. https:\/\/doi.org\/10.1007\/s11357-025-01830-3.","journal-title":"Geroscience"},{"issue":"10","key":"10839_CR28","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1016\/j.biocel.2013.05.019","volume":"45","author":"HQ Han","year":"2013","unstructured":"Han HQ, Zhou X, Mitch WE, Goldberg AL. Myostatin\/activin pathway antagonism: molecular basis and therapeutic potential. Int J Biochem Cell Biol. 2013;45(10):2333\u201347. https:\/\/doi.org\/10.1016\/j.biocel.2013.05.019.","journal-title":"Int J Biochem Cell Biol"},{"issue":"20","key":"10839_CR29","doi-asserted-by":"publisher","first-page":"7230","DOI":"10.1128\/MCB.23.20.7230-7242.2003","volume":"23","author":"A Rebbapragada","year":"2003","unstructured":"Rebbapragada A, Benchabane H, Wrana JL, Celeste AJ, Attisano L. Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis. Mol Cell Biol. 2003;23(20):7230\u201342. https:\/\/doi.org\/10.1128\/MCB.23.20.7230-7242.2003.","journal-title":"Mol Cell Biol"},{"key":"10839_CR30","doi-asserted-by":"publisher","first-page":"785712","DOI":"10.3389\/fcell.2021.785712","volume":"9","author":"MM Chen","year":"2021","unstructured":"Chen MM, Zhao YP, Zhao Y, Deng SL, Yu K. Regulation of myostatin on the growth and development of skeletal muscle. Front Cell Dev Biol. 2021;9:785712. https:\/\/doi.org\/10.3389\/fcell.2021.785712.","journal-title":"Front Cell Dev Biol"},{"key":"10839_CR31","doi-asserted-by":"publisher","first-page":"114513","DOI":"10.1016\/j.ygcen.2024.114513","volume":"353","author":"XQ Lan","year":"2024","unstructured":"Lan XQ, Deng CJ, Wang QQ, Zhao LM, Jiao BW, Xiang Y. The role of TGF-\u03b2 signaling in muscle atrophy, sarcopenia and cancer cachexia. Gen Comp Endocrinol. 2024;353:114513. https:\/\/doi.org\/10.1016\/j.ygcen.2024.114513.","journal-title":"Gen Comp Endocrinol"},{"issue":"9","key":"10839_CR32","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/j.cellsig.2011.05.003","volume":"23","author":"Z Huang","year":"2011","unstructured":"Huang Z, Chen X, Chen D. Myostatin: a novel insight into its role in metabolism, signal pathways, and expression regulation. Cell Signal. 2011;23(9):1441\u20136. https:\/\/doi.org\/10.1016\/j.cellsig.2011.05.003.","journal-title":"Cell Signal"},{"issue":"1","key":"10839_CR33","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.116.021884","volume":"134","author":"SJ Shah","year":"2016","unstructured":"Shah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, Kass DA, et al. Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation. 2016;134(1):73\u201390. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.021884.","journal-title":"Circulation"},{"key":"10839_CR34","doi-asserted-by":"publisher","first-page":"101880","DOI":"10.1016\/j.molmet.2024.101880","volume":"80","author":"E Nunn","year":"2024","unstructured":"Nunn E, Jaiswal N, Gavin M, Uehara K, Stefkovich M, Drareni K, et al. Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism. Mol Metab. 2024;80:101880. https:\/\/doi.org\/10.1016\/j.molmet.2024.101880.","journal-title":"Mol Metab"},{"issue":"3","key":"10839_CR35","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/ijo.2015.200","volume":"40","author":"J Dong","year":"2016","unstructured":"Dong J, Dong Y, Dong Y, Chen F, Mitch WE, Zhang L. Inhibition of myostatin in mice improves insulin sensitivity via irisin-mediated cross talk between muscle and adipose tissues. Int J Obes (Lond). 2016;40(3):434\u201342. https:\/\/doi.org\/10.1038\/ijo.2015.200.","journal-title":"Int J Obes (Lond)"},{"issue":"7382","key":"10839_CR36","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nature10777","volume":"481","author":"P Bostr\u00f6m","year":"2012","unstructured":"Bostr\u00f6m P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, et al. A PGC1-\u03b1-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481(7382):463\u20138. https:\/\/doi.org\/10.1038\/nature10777.","journal-title":"Nature"},{"issue":"5","key":"10839_CR37","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1096\/fj.12-225755","volume":"27","author":"T Shan","year":"2013","unstructured":"Shan T, Liang X, Bi P, Kuang S. Myostatin knockout drives browning of white adipose tissue through activating the AMPK-PGC1\u03b1-Fndc5 pathway in muscle. FASEB J. 2013;27(5):1981\u20139. https:\/\/doi.org\/10.1096\/fj.12-225755.","journal-title":"FASEB J"},{"issue":"8","key":"10839_CR38","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrendo.2012.49","volume":"8","author":"BK Pedersen","year":"2012","unstructured":"Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012;8(8):457\u201365. https:\/\/doi.org\/10.1038\/nrendo.2012.49.","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"10839_CR39","doi-asserted-by":"publisher","first-page":"e2033457","DOI":"10.1001\/jamanetworkopen.2020.33457","volume":"4","author":"SB Heymsfield","year":"2021","unstructured":"Heymsfield SB, Coleman LA, Miller R, Rooks DS, Laurent D, Petricoul O, et al. Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial. JAMA Netw Open. 2021;4(1):e2033457. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.33457.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10839_CR40","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41574-022-00783-3","volume":"19","author":"R Hammoud","year":"2023","unstructured":"Hammoud R, Drucker DJ. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nat Rev Endocrinol. 2023;19(4):201\u201316. https:\/\/doi.org\/10.1038\/s41574-022-00783-3.","journal-title":"Nat Rev Endocrinol"},{"key":"10839_CR41","doi-asserted-by":"publisher","first-page":"100518","DOI":"10.1016\/j.ahjo.2025.100518","volume":"52","author":"C Odigwe","year":"2025","unstructured":"Odigwe C, Mulyala R, Malik H, Ruiz B, Riad M, Sayiadeh MA, et al. Emerging role of GLP-1 agonists in cardio-metabolic therapy \u2014 focus on semaglutide. Am Heart J Plus. 2025;52:100518. https:\/\/doi.org\/10.1016\/j.ahjo.2025.100518.","journal-title":"Am Heart J Plus"},{"issue":"3","key":"10839_CR42","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2206038.","journal-title":"N Engl J Med"},{"issue":"10295","key":"10839_CR43","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","volume":"398","author":"J Rosenstock","year":"2021","unstructured":"Rosenstock J, Wysham C, Fr\u00edas JP, Kaneko S, Lee CJ, Fern\u00e1ndez Land\u00f3 L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(21)01324-6.","journal-title":"Lancet"},{"issue":"4","key":"10839_CR44","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.cmet.2017.03.005","volume":"25","author":"LD BonDurant","year":"2017","unstructured":"BonDurant LD, Ameka M, Naber MC, Markan KR, Idiga SO, Acevedo MR, et al. FGF21 regulates metabolism through adipose-dependent and -independent mechanisms. Cell Metab. 2017;25(4):935-44.e4. https:\/\/doi.org\/10.1016\/j.cmet.2017.03.005.","journal-title":"Cell Metab"},{"issue":"7795","key":"10839_CR45","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s41586-019-1911-y","volume":"578","author":"AP Coll","year":"2020","unstructured":"Coll AP, Chen M, Taskar P, Rimmington D, Patel S, Tadross JA, et al. GDF15 mediates the effects of metformin on body weight and energy balance. Nature. 2020;578(7795):444\u20138. https:\/\/doi.org\/10.1038\/s41586-019-1911-y.","journal-title":"Nature"},{"issue":"1","key":"10839_CR46","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1373\/clinchem.2016.255174","volume":"63","author":"KC Wollert","year":"2017","unstructured":"Wollert KC, Kempf T, Wallentin L. Growth differentiation factor 15 as a biomarker in cardiovascular disease. Clin Chem. 2017;63(1):140\u201351. https:\/\/doi.org\/10.1373\/clinchem.2016.255174.","journal-title":"Clin Chem"},{"issue":"412","key":"10839_CR47","doi-asserted-by":"publisher","first-page":"eaan8732","DOI":"10.1126\/scitranslmed.aan8732","volume":"9","author":"Y Xiong","year":"2017","unstructured":"Xiong Y, Walker K, Min X, Hale C, Tran T, Komorowski R, et al. Long-acting MIC-1\/GDF15 molecules to treat obesity: evidence from mice to monkeys. Sci Transl Med. 2017;9(412):eaan8732. https:\/\/doi.org\/10.1126\/scitranslmed.aan8732.","journal-title":"Sci Transl Med"},{"issue":"3","key":"10839_CR48","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cmet.2018.12.016","volume":"29","author":"S Patel","year":"2019","unstructured":"Patel S, Alvarez-Guaita A, Melvin A, Rimmington D, Dattilo A, Miedzybrodzka EL, et al. GDF15 provides an endocrine signal of nutritional stress in mice and humans. Cell Metab. 2019;29(3):707-18.e8. https:\/\/doi.org\/10.1016\/j.cmet.2018.12.016.","journal-title":"Cell Metab"},{"issue":"2","key":"10839_CR49","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cmet.2022.12.011","volume":"35","author":"O Benichou","year":"2023","unstructured":"Benichou O, Coskun T, Gonciarz MD, Garhyan P, Adams AC, Du Y, et al. Discovery, development, and clinical proof of mechanism of LY3463251, a long-acting GDF15 receptor agonist. Cell Metab. 2023;35(2):274-86.e10. https:\/\/doi.org\/10.1016\/j.cmet.2022.12.011.","journal-title":"Cell Metab"},{"issue":"1","key":"10839_CR50","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12968-016-0308-4","volume":"18","author":"P Haaf","year":"2016","unstructured":"Haaf P, Garg P, Messroghli DR, Broadbent DA, Greenwood JP, Plein S. Cardiac T1 mapping and extracellular volume (ECV) in clinical practice: a comprehensive review. J Cardiovasc Magn Reson. 2016;18(1):89. https:\/\/doi.org\/10.1186\/s12968-016-0308-4.","journal-title":"J Cardiovasc Magn Reson"},{"issue":"5","key":"10839_CR51","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/ana.21338","volume":"63","author":"KR Wagner","year":"2008","unstructured":"Wagner KR, Fleckenstein JL, Amato AA, Barohn RJ, Bushby K, Escolar DM, et al. A phase I\/II trial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol. 2008;63(5):561\u201371. https:\/\/doi.org\/10.1002\/ana.21338.","journal-title":"Ann Neurol"},{"issue":"4","key":"10839_CR52","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/mus.25268","volume":"55","author":"C Campbell","year":"2017","unstructured":"Campbell C, McMillan HJ, Mah JK, Tarnopolsky M, Selby K, McClure T, et al. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial. Muscle Nerve. 2017;55(4):458\u201364. https:\/\/doi.org\/10.1002\/mus.25268.","journal-title":"Muscle Nerve"},{"issue":"12","key":"10839_CR53","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S2213-8587(15)00298-3","volume":"3","author":"C Becker","year":"2015","unstructured":"Becker C, Lord SR, Studenski SA, Warden SJ, Fielding RA, Recknor CP, et al. Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial. Lancet Diabetes Endocrinol. 2015;3(12):948\u201357. https:\/\/doi.org\/10.1016\/S2213-8587(15)00298-3.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10839_CR54","doi-asserted-by":"publisher","first-page":"62","DOI":"10.14283\/jfa.2016.81","volume":"5","author":"L Woodhouse","year":"2016","unstructured":"Woodhouse L, Gandhi R, Warden SJ, Poiraudeau S, Myers SL, Benson CT, et al. A phase 2 randomized study investigating the efficacy and safety of myostatin antibody LY2495655 versus placebo in patients undergoing elective total hip arthroplasty. J Frailty Aging. 2016;5(1):62\u201370. https:\/\/doi.org\/10.14283\/jfa.2016.81.","journal-title":"J Frailty Aging"},{"issue":"9","key":"10839_CR55","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1111\/jgs.14927","volume":"65","author":"D Rooks","year":"2017","unstructured":"Rooks D, Praestgaard J, Hariry S, Laurent D, Petricoul O, Perry RG, et al. Treatment of sarcopenia with bimagrumab: results from a phase II, randomized, controlled, proof-of-concept study. J Am Geriatr Soc. 2017;65(9):1988\u201395. https:\/\/doi.org\/10.1111\/jgs.14927.","journal-title":"J Am Geriatr Soc"},{"issue":"10","key":"10839_CR56","doi-asserted-by":"publisher","first-page":"e2020836","DOI":"10.1001\/jamanetworkopen.2020.20836","volume":"3","author":"D Rooks","year":"2020","unstructured":"Rooks D, Swan T, Goswami B, Filosa LA, Bunte O, Panchaud N, et al. Bimagrumab vs optimized standard of care for treatment of sarcopenia in community-dwelling older adults: a randomized clinical trial. JAMA Netw Open. 2020;3(10):e2020836. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.20836.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10839_CR57","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827.","journal-title":"N Engl J Med"},{"issue":"19","key":"10839_CR58","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1607141.","journal-title":"N Engl J Med"},{"issue":"24","key":"10839_CR59","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2307563.","journal-title":"N Engl J Med"},{"issue":"16","key":"10839_CR60","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2107038.","journal-title":"N Engl J Med"},{"issue":"3","key":"10839_CR61","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jchf.2021.11.006","volume":"10","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, Vaduganathan M, Claggett BL, de Boer RA, DeMets D, Hernandez AF, et al. Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction: DELIVER trial. JACC Heart Fail. 2022;10(3):184\u201397. https:\/\/doi.org\/10.1016\/j.jchf.2021.11.006.","journal-title":"JACC Heart Fail"},{"issue":"11","key":"10839_CR62","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183.","journal-title":"N Engl J Med"},{"issue":"9","key":"10839_CR63","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nrneph.2014.112","volume":"10","author":"XH Wang","year":"2014","unstructured":"Wang XH, Mitch WE. Mechanisms of muscle wasting in chronic kidney disease. Nat Rev Nephrol. 2014;10(9):504\u201316. https:\/\/doi.org\/10.1038\/nrneph.2014.112.","journal-title":"Nat Rev Nephrol"},{"key":"10839_CR64","doi-asserted-by":"publisher","first-page":"101569","DOI":"10.1016\/j.arr.2022.101569","volume":"75","author":"M Conte","year":"2022","unstructured":"Conte M, Giuliani C, Chiariello A, Iannuzzi V, Franceschi C, Salvioli S. GDF15, an emerging key player in human aging. Ageing Res Rev. 2022;75:101569. https:\/\/doi.org\/10.1016\/j.arr.2022.101569.","journal-title":"Ageing Res Rev"},{"issue":"1","key":"10839_CR65","doi-asserted-by":"publisher","first-page":"4376","DOI":"10.1038\/s41467-025-59380-3","volume":"16","author":"D Gonzalez Trotter","year":"2025","unstructured":"Gonzalez Trotter D, Donahue S, Wynne C, Ali S, Parasoglou P, Boyapati A, et al. GDF8 and activin A are the key negative regulators of muscle mass in postmenopausal females: a randomized phase I trial. Nat Commun. 2025;16(1):4376. https:\/\/doi.org\/10.1038\/s41467-025-59380-3.","journal-title":"Nat Commun"},{"issue":"1","key":"10839_CR66","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.cmet.2015.05.010","volume":"22","author":"MA Egerman","year":"2015","unstructured":"Egerman MA, Cadena SM, Gilbert JA, Meyer A, Nelson HN, Swalley SE, et al. GDF11 increases with age and inhibits skeletal muscle regeneration. Cell Metab. 2015;22(1):164\u201374. https:\/\/doi.org\/10.1016\/j.cmet.2015.05.010.","journal-title":"Cell Metab"}],"container-title":["Journal of Cardiovascular Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-026-10839-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12265-026-10839-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-026-10839-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:34:18Z","timestamp":1787841258000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12265-026-10839-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["10839"],"URL":"https:\/\/doi.org\/10.1007\/s12265-026-10839-8","relation":{},"ISSN":["1937-5387","1937-5395"],"issn-type":[{"value":"1937-5387","type":"print"},{"value":"1937-5395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"assertion":[{"value":"4 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This study presents a conceptual framework and does not involve human or animal subjects.","order":1,"name":"Ethics","label":"Ethical Statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"108"}}